Erika Mohr - Publications

Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: October 17, 2019

Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.

Journal: The Lancet. Infectious diseases

Published: March 06, 2019

'I didn't know so many people cared about me': support for patients who interrupt drug-resistant TB treatment.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: August 11, 2018

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.

Journal: The European respiratory journal

Published: August 11, 2018

"Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa.

Journal: PloS one

Published: May 03, 2018

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Journal: Lancet (London, England)

Published: February 24, 2018

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.

Journal: The European respiratory journal

Published: January 10, 2018

Missed opportunities for earlier diagnosis of rifampicin-resistant tuberculosis despite access to Xpert® MTB/RIF.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: September 16, 2017

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.

Journal: The Lancet. Infectious diseases

Published: August 14, 2017

Six-Month Response to Delamanid Treatment in MDR TB Patients.

Journal: Emerging infectious diseases

Published: August 03, 2017

DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.

Journal: PloS one

Published: February 08, 2017

Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study.

Journal: PloS one

Published: July 11, 2016